Prostate Cancer

Praful K. Ravi, MB, BChir, MRCP, discusses the use of residual cancer burden to guide intensified neoadjuvant treatment in high-risk prostate cancer.

Jun Gong, MD, discusses the benefits and limitations of PARP inhibitor–based regimens in metastatic castration-resistant prostate cancer.

Alicia Morgans, MD, MPH, discusses key data from the follow-up analysis of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

The FDA has accepted the new drug application for the new TLX007-CDx cold kit for the preparation of PSMA-PET imaging in patients with prostate cancer.

Marc-Oliver Grimm, MD, discusses a post-hoc analysis of the ARASENS trial in metastatic hormone-sensitive prostate cancer.

Alicia Morgans, MD, MPH, discusses data from the ARAMIS trial showing the association between PSA levels and radiological progression in nmCRPC.

Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.

Key opinion leaders outline a case study of a patient with metastatic castration-sensitive prostate cancer, detailing the chosen treatment approaches and the overall outcome of the case.

Darolutamide plus ADT improved radiologic PFS vs placebo plus ADT in men with metastatic hormone-sensitive prostate cancer enrolled in the phase 3 ARANOTE trial.

A 100-mg dose of tarlatamab was safe and showed particularly robust activity in patients with DLL3-positive neuroendocrine prostate cancer.

The FDA has granted fast track designation to BNT324/DB-1311 for metastatic castration-resistant prostate cancer.

S. Lindsey Davis, MD, highlights data with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib in patients with solid tumors.

The FDA has granted fast track designation to the radiopharmaceutical 225Ac-FL-020 for patients with metastatic castration-resistant prostate cancer.

The FDA has approved a companion diagnostic for niraparib plus abiraterone acetate in BRCA-mutated metastatic castration-resistant prostate cancer.

Stephen J. Freedland, MD, discusses the effects of treatment suspension on HRQOL in nonmetastatic hormone-sensitive prostate cancer in the EMBARK trial.

Christos Kyriakopoulos, MD discusses adding cabazitaxel to abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer.

Darolutamide plus ADT and docetaxel showed improved outcomes in patients with metastatic hormone-sensitive prostate cancer.

Marc-Oliver Grimm, MD discusses darolutamide in combination with androgen deprivation therapy and docetaxel in mHSPC.

Atish D. Choudhury, MD, PhD, on a phase 2 trial evaluating ADT interruption in metastatic hormone-sensitive prostate cancer after AR inhibitor response.

Hypofractionation radiotherapy was noninferior to conventional fractionation radiotherapy for the treatment of patients with low-risk prostate cancer.

A novel radioligand therapy, JNJ-6420, demonstrates potential in treating mCRPCr, delivering sustained responses following only 1-2 doses.

The investigational PROTAC AR degrader ARV-766 showed promising clinical activity and tolerability in patients with metastatic castration-resistant prostate cancer.

Pembrolizumab and platinum-based therapy elicited safe and efficacious outcomes in penile squamous cell carcinoma.

Apalutamide/ADT maintains quality of life, demonstrates improved PSA progression-free survival in recurrent prostate cancer according to PRESTO trial.

Anthony V. D'Amico, MD, PhD, discusses the Decipher Genomic Classifier in prostate cancer treatment.